Evidence map›Paper›PMID 38392595›Full record

ArticleJournal of personalized medicine2024

Reversibility of the Enlargement of the Pulmonary Artery in COVID-19 Pneumonia as a Marker of Remission of the Disease.

Andreas M Matthaiou, Nikoleta Bizymi, Konstantinos Pagonidis, Eirini Manousaki, Michail Fragkoulakis, Irini Lambiri, Ioanna Mitrouska, Eirini Vasarmidi, Nikolaos Tzanakis, Katerina M Antoniou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Andreas M MatthaiouLaboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, 71500 Heraklion, Greece.ORCID 0000-0003-1941-0213
Nikoleta BizymiLaboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, 71500 Heraklion, Greece.ORCID 0000-0001-5199-1519
Konstantinos PagonidisDepartment of Medical Imaging, Knossos Medical Diagnosis Centre, 71409 Heraklion, Greece.
Eirini ManousakiDepartment of Medical Imaging, Knossos Medical Diagnosis Centre, 71409 Heraklion, Greece.
Michail FragkoulakisDepartment of Medical Imaging, Knossos Medical Diagnosis Centre, 71409 Heraklion, Greece.
Irini LambiriDepartment of Respiratory Medicine, University Hospital of Heraklion, 71500 Heraklion, Greece.
Ioanna MitrouskaDepartment of Respiratory Medicine, University Hospital of Heraklion, 71500 Heraklion, Greece.
Eirini VasarmidiLaboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, 71500 Heraklion, Greece.ORCID 0000-0003-0747-0227
Nikolaos TzanakisLaboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, 71500 Heraklion, Greece.
Katerina M AntoniouLaboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, 71500 Heraklion, Greece.
University of Crete · GRUniversity Hospital of Heraklion · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) pneumonia is associated with extensive pulmonary microangiopathy and the enlargement of the pulmonary artery (PA), while its progression after the remission of the disease has not been investigated yet. The aim was to assess the diametral increase in the PA in COVID-19 pneumonia, as revealed on chest computed tomography (CT), and further investigate its progression. This was a retrospective cohort study of patients with COVID-19 pneumonia, without prior history of pulmonary hypertension, who underwent CT pulmonary angiography before, during, and after the infection. Pulmonary embolism was excluded in all cases. The main PA diameter (MPAD) was assessed in consecutive chest imaging. Statistical analysis was performed with the non-parametric Wilcoxon and Kruskal-Wallis tests, while correlations were performed with the non-parametric Spearman test. A mean ± SD MPAD of 3.1 ± 0.3 cm in COVID-19 pneumonia was significantly decreased to 2.8 ± 0.3 cm in the post-infectious state after 2-18 months in 31 patients (

Indexed as

chest imagingCOVID-19pulmonary artery enlargementpulmonary hypertension

Identifiers

PMID38392595
PMCPMC10890114
OpenAlexW4391386192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.